Startup profile · funding coverage
Octant Bio funding, valuation and investors
Synthetic-biology platform mapping GPCR drug targets using engineered human cell reporters.
Keep track of Octant Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
undisclosed · April 2022
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$30M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Emeryville, California, USA
Overview
Octant Bio (often styled Octant) uses synthetic biology to discover drugs against G protein-coupled receptors (GPCRs), a large but historically hard-to-drug target class. The company engineers human cell lines that report receptor activity, then screens compounds at scale to build comprehensive maps linking chemistry to biology. Founded by Sri Kosuri, a UCLA professor and DNA synthesis pioneer, Octant raised a $30M Series A led by a16z in May 2020 with 8VC participating, followed by additional financing bringing total funding to roughly $115M per Tracxn. The approach replaces slower traditional assays with programmable cellular reporters.
Why Octant Bio is interesting
Sri Kosuri’s “antedisciplinary” lab turned programmable cell lines into a drug-discovery map — a16z led Series A and 8VC joined before a ~$115M total raise for industrial-scale receptor screening.
Product & use cases
Octant builds engineered human cell lines that function as living sensors for GPCR activity. The platform screens chemical libraries to produce high-dimensional maps of how molecules modulate receptors — accelerating target validation and lead discovery for internal and partnered programs.
- Mapping understudied GPCR targets for new therapeutic programs
- High-throughput phenotypic screening vs traditional binding assays
- Partnering with pharma on receptor biology datasets
- Identifying polypharmacology and off-target effects early in discovery
Key facts
- Series A (May 2020): $30M led by a16z; 8VC participated — a16z announcement, GenomeWeb
- Series B (Apr 2022): additional financing; total raised ~$115M per Tracxn
- Founded by Sri Kosuri, UCLA professor and co-founder of DNA synthesis company Twist Bioscience alumni network
- Focus: GPCR target class — largest family of membrane drug targets
- Co-investors not in VCT directory: Catalio Capital, SV Angel
Funding history (newest first)
Series B
2022-04 undisclosedSource: https://www.genomeweb.com/business-news/octant-raises-85m-series-b-financing
Series A
2020-05 $30MInvestors in our directory
Funds linked from Octant Bio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Programmable cell reporters scale GPCR exploration beyond one-target-at-a-time workflows. Kosuri’s DNA synthesis background informs industrial biology execution rare in early-stage biotech.
GPCRs remain a major drug target class with high failure rates in traditional screening. Octant’s bet is that engineered reporters plus scale produce better target–ligand maps than incremental assay tweaks. Competition includes techbio platforms (Recursion, Insitro) and pharma in-house labs. Success depends on translating maps into clinical candidates — still early for most platform biotechs.
-
Recursion Pharmaceuticals adjacent
Phenotypic screening at scale with imaging and ML; broader target classes vs Octant’s GPCR-specific synthetic biology focus.
-
Traditional pharma HTS incumbent
Big pharma internal screening infrastructure; Octant sells speed and receptor map completeness.
-
Insitro adjacent
ML-driven drug discovery with cellular models; overlapping “techbio” thesis but different core platform.
-
Conceivable Life Sciences direct
Other synthetic biology drug discovery shops targeting difficult protein classes.
Notable stories
- Kosuri coined “antedisciplinary science” to describe Octant’s blend of synthetic biology, chemistry, and computation — a framing he used when launching the company out of UCLA research.
- a16z’s 2020 Octant investment was among its early bio platform bets predating the a16z Bio + Health split.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Octant Bio's financing or category context.
FAQs about Octant Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.